[go: up one dir, main page]

AU2002307062A1 - Thrombopoietin (tpo) synthebody for stimulation of platelet production - Google Patents

Thrombopoietin (tpo) synthebody for stimulation of platelet production

Info

Publication number
AU2002307062A1
AU2002307062A1 AU2002307062A AU2002307062A AU2002307062A1 AU 2002307062 A1 AU2002307062 A1 AU 2002307062A1 AU 2002307062 A AU2002307062 A AU 2002307062A AU 2002307062 A AU2002307062 A AU 2002307062A AU 2002307062 A1 AU2002307062 A1 AU 2002307062A1
Authority
AU
Australia
Prior art keywords
synthebody
thrombopoietin
tpo
stimulation
platelet production
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2002307062A
Other languages
English (en)
Inventor
Ronald M. Burch
Robert A. Ogert
Daniel A. Soltis
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Purdue Pharma LP
Original Assignee
Purdue Pharma LP
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Purdue Pharma LP filed Critical Purdue Pharma LP
Publication of AU2002307062A1 publication Critical patent/AU2002307062A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2318/00—Antibody mimetics or scaffolds
    • C07K2318/10—Immunoglobulin or domain(s) thereof as scaffolds for inserted non-Ig peptide sequences, e.g. for vaccination purposes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
AU2002307062A 2001-04-02 2002-04-02 Thrombopoietin (tpo) synthebody for stimulation of platelet production Abandoned AU2002307062A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US28118301P 2001-04-02 2001-04-02
US60/281,183 2001-04-02
PCT/US2002/010301 WO2002078612A2 (fr) 2001-04-02 2002-04-02 Anticorps synthetique contenant de la thrombopoietine (tpo) pour la stimulation de la production de plaquettes

Publications (1)

Publication Number Publication Date
AU2002307062A1 true AU2002307062A1 (en) 2002-10-15

Family

ID=23076287

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002307062A Abandoned AU2002307062A1 (en) 2001-04-02 2002-04-02 Thrombopoietin (tpo) synthebody for stimulation of platelet production

Country Status (2)

Country Link
AU (1) AU2002307062A1 (fr)
WO (1) WO2002078612A2 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2010200100B2 (en) * 2002-09-18 2013-05-23 Ortho-Mcneil Pharmaceutical, Inc. Methods of increasing platelet and hematopoietic stem cell production

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7531643B2 (en) 1997-09-11 2009-05-12 Chugai Seiyaku Kabushiki Kaisha Monoclonal antibody inducing apoptosis
ME00238B (me) 1998-10-23 2011-02-10 Kirin Amgen Inc Mimičko vezivanje dimernog trombopoitetinskog peptida za mp1 receptor sa trombopoietičkom aktivnošću
AU1091702A (en) * 2000-10-20 2002-04-29 Chugai Pharmaceutical Co Ltd Degraded tpo agonist antibody
EP2351838A1 (fr) * 2000-10-20 2011-08-03 Chugai Seiyaku Kabushiki Kaisha Anticorps agonistiques qui réticuler
EP1327681A4 (fr) * 2000-10-20 2004-09-01 Chugai Pharmaceutical Co Ltd Anticorps agoniste degrade
DE60136656D1 (de) 2000-12-05 2009-01-02 Alexion Pharma Inc Rationell entworfene Antikörper
AU2003295623B2 (en) * 2000-12-05 2008-06-05 Alexion Pharmaceuticals, Inc. Rationally designed antibodies
US7396917B2 (en) 2000-12-05 2008-07-08 Alexion Pharmaceuticals, Inc. Rationally designed antibodies
US7332474B2 (en) * 2001-10-11 2008-02-19 Amgen Inc. Peptides and related compounds having thrombopoietic activity
AU2003230830A1 (en) * 2002-04-09 2003-10-27 The Curators Of The University Of Missouri Treatment of type 1 diabetes before and after expression of predisposition markers
JP2004279086A (ja) 2003-03-13 2004-10-07 Konica Minolta Holdings Inc 放射線画像変換パネル及び放射線画像変換パネルの製造方法
WO2004096154A2 (fr) * 2003-04-29 2004-11-11 Smithkline Beecham Corporation Procedes de traitement de maladies/lesions degeneratives
US7723295B2 (en) 2003-08-28 2010-05-25 Ortho-Mcneil Pharmaceutical, Inc. Peptides and compounds that bind to a receptor
EA009286B1 (ru) 2003-08-28 2007-12-28 Орто-Макнейл Фармасьютикал, Инк. Пептиды и соединения, которые связываются с рецептором
WO2005021595A1 (fr) * 2003-08-28 2005-03-10 Euro-Celtique S.A. Procedes utilisant les regles des regions de presentation des anticorps pour intervenir sur des anticorps
TW200530269A (en) * 2003-12-12 2005-09-16 Chugai Pharmaceutical Co Ltd Anti-Mpl antibodies
TW200722518A (en) 2005-03-31 2007-06-16 Chugai Pharmaceutical Co Ltd Sc(fv)2 structural isomers
JP5620626B2 (ja) 2005-03-31 2014-11-05 中外製薬株式会社 会合制御によるポリペプチド製造方法
EP1908482B1 (fr) 2005-06-10 2017-09-06 Chugai Seiyaku Kabushiki Kaisha Stabilisant pour une préparation de protéine contenant de la méglumine et son utilisation
US9241994B2 (en) 2005-06-10 2016-01-26 Chugai Seiyaku Kabushiki Kaisha Pharmaceutical compositions containing sc(Fv)2
AU2007208226A1 (en) * 2006-01-25 2007-08-02 Amgen Inc. Thrombopoietic compounds
EP4218801A3 (fr) 2006-03-31 2023-08-23 Chugai Seiyaku Kabushiki Kaisha Procédé de modification d'anticorps pour purifier un anticorps bispécifique
US20140047572A1 (en) * 2012-08-13 2014-02-13 University Of Rochester Thrombopoietin mimetics for the treatment of radiation or chemical induced bone marrow injury
CN105764922B (zh) 2013-09-27 2020-07-17 中外制药株式会社 多肽异源多聚体的制备方法
US11649262B2 (en) 2015-12-28 2023-05-16 Chugai Seiyaku Kabushiki Kaisha Method for promoting efficiency of purification of Fc region-containing polypeptide
EP3553082A1 (fr) * 2018-04-12 2019-10-16 Bayer Aktiengesellschaft Anticorps greffés de peptide natriurétique du cerveau
EP3553079A1 (fr) * 2018-04-12 2019-10-16 Bayer Aktiengesellschaft Anticorps greffés de peptide natriurétique de type c
EP3553081A1 (fr) * 2018-04-12 2019-10-16 Bayer Aktiengesellschaft Anticorps greffés de peptide natriurétique auriculaire
WO2025002113A1 (fr) * 2023-06-26 2025-01-02 上海济煜医药科技有限公司 Protéine de fusion d'agoniste du récepteur de la thrombopoïétine humaine

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0460076T3 (da) * 1989-02-24 1996-03-25 Univ California Genetisk manipulerede immunoglobuliner
AR003431A1 (es) * 1995-06-07 1998-08-05 Glaxo Group Ltd Peptidos compuestos que se ligan al receptor de trombopoietina.

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2010200100B2 (en) * 2002-09-18 2013-05-23 Ortho-Mcneil Pharmaceutical, Inc. Methods of increasing platelet and hematopoietic stem cell production

Also Published As

Publication number Publication date
WO2002078612A2 (fr) 2002-10-10
WO2002078612A3 (fr) 2003-04-03

Similar Documents

Publication Publication Date Title
AU2002307062A1 (en) Thrombopoietin (tpo) synthebody for stimulation of platelet production
AU2003242566A1 (en) Production of olefins
AU2002257936A1 (en) Methods of well treatment
AU2002226622A1 (en) Production of hydrocarbon products
AU2002348144A1 (en) Improved production of electroluminescent devices
AU2003255456A1 (en) Production of olefins
AU2002316896A1 (en) Method for the production of nanodispersions
AU2002255657A1 (en) Production of polyhydroxyalkanoates
AU2003206803A1 (en) Production of alkenones
AU2002247848A1 (en) Methods for the production of minicircles
AU2001265935A1 (en) Production of biohydrolysates
AU2002329441A1 (en) Process for the preparation of 3 - isochromanone
AU2002335992A1 (en) Process for the production of ascopyrone p
AU2002358085A1 (en) Process for the preparation of 4-methyl-7-aminoquinolones
AU2003243432A1 (en) Process of making phosphordiamidite compounds
AU2002324291A1 (en) Process for the preparation of beta-ionylideneacetaldehyde
AU2002334411A1 (en) Production of usppase
AU2002352014A1 (en) Method for the production of organodiphosphonites
AU2002358483A1 (en) Production of polyamide
AU2002245360A1 (en) Production of higher olefins
AU2002359898A1 (en) Preparation of alpha-diimines
AUPR966901A0 (en) Production of gemstones
AU2002254735A1 (en) Production of diisopropylbenzene
AU2003285530A1 (en) Production of biocompounds
AU2003212653A1 (en) Production of ugppase

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase